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5 patients, 1 died 3 days after diagnosis. 4 patients had 
surgery, 3 developed DM and 1 is a long-term survivor. 
Median OS was 68 days. 
 
 
 
Conclusion: These rare sarcomas have variable clinical 
presentations. Surgery is the central component for 
successful treatment but complete resection is not always 
possible. RT may reduce LR (reduced from 77%, group B,to 
53%, group A) and chemotherapy is offered if high risk 
(inoperable, R2 margins, or DM). We still need to define the 
optimum management. 
 
PO-0766  
Is dose de-escalation possible in sarcoma patients treated 
with extended limb sparing resection? 
A. Levy
1Institut Gustave Roussy, Radiation Oncology department, 
Villejuif, France 
1, S. Bonvalot2, P. Terrier3, A. Le Cesne4, C. Le 
Péchoux5 
2Curie, Surgery, Paris, France 
3Gustave Roussy, Pathology, Villejuif, France 
4Gustave Roussy, Medicine, Vilejuif, France 
5Gustave Roussy, radiation Oncology, Villejuif, France 
 
Purpose or Objective: To evaluate the impact of a dose 
escalation > 50 Gy in a large series of resected limbs soft 
tissue sarcomas (STS) 
 
Material and Methods: Data were retrospectively analyzed 
from 414 consecutive localized limbs STS patients who 
received irradiation and enlarged surgery at Gustave Roussy 
from 05/1993 to 05/2012. RT dose level were decided in 
multidisciplinary staff and depended upon the quality of 
surgery and margins size. 
 
Results: The median age was 52 years, the median tumor size 
was 89 mm, most patients had proximal locations (72%), and 
G-2-3 tumors (79%). Available histologic analyses after 
surgery retrieved 84% unifocal tumors and free-tumor margins 
>1 mm in 69% of cases. Radiotherapy (RT) was delivered prior 
(13%) or after (87%) surgery. Seven patients (2%) had pre- and 
a postoperative RT boost. Median delivered RT dose was 50 
Gy (36-70 Gy), and 40% received >50Gy. At a median follow-
up of 5.5 years, the 5-year local relapse rates (LRRs) were 
7%, 4%, and 13% in the general population, in patients 
receiving <50Gy and in those who had >50 Gy (p<0.001), 
respectively. Despite this may due to confounding factors, a 
dose >50 Gy (HR: 2.6; p=0.04) remained associated with 
higher LRRs in the multivariate analysis (MVA), as well as 
histological subtypes (HR: 3.7; p=0.002), and surgical 
margins<1mm (HR: 3.2; p=0.008). Grade, age, and tumour 
size were not associated with LRRs in the MVA. 
 
Conclusion: In this retrospective analysis of patients having 
enlarged and surgery and RT dose escalation did not allow 
offsetting local relapse in high-risk patients. This should be 
evaluated in a larger set of patients all having enlarged 
surgery. A Prospective study allowing dose refinement in this 
setting is required. 
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Purpose or Objective: Fluid collection of lymph or blood may 
accumulate at the site of excision after surgery for soft tissue 
sarcoma, with reported incidence rates from 10-36%. Though 
small fluid collections have a high probability of being 
completely covered within the postoperative radiotherapy 
(PORT) field, large fluid collections may require a more 
extensive expansion of CTVs. This study is an unprecedented 
analysis of fluid collection in relation to radiotherapy 
outcomes after wide excision of soft tissue sarcoma (STS). 
 
Material and Methods: Medical records of 151 patients with 
STS treated with wide excision followed by adjuvant PORT 
between 2004 and 2014 were retrospectively reviewed. Only 
non-recurrent and non-metastatic patients were included. 
After evaluation of CT and MR images taken at the time of 
PORT planning, fluid collection was detected in 46 patients 
(30.5%). Because fluid collection developed more commonly 
in lower extremity (p<0.001) and higher grade tumors 
(p=0.095), only these patients were included in further 
analyses (n=76). Fluid collection was present in 35 (46.1%) 
patients, of which 74.3% and 25.7% had, respectively, either 
complete or partial coverage in planning target volumes 
(PTVs) throughout the entire course of PORT. 
 
Results: After a median follow-up of 41 months, patients 
with and without fluid collection demonstrated local failure 
rates of 14.3% and 9.8%, and 5-year local control (LC) rates of 
83.1% and 86.8%, respectively. The presence of fluid 
collection had no statistical impact on the clinical outcomes 
of PORT. Partial coverage of fluid collection showed a low 5-
year LC rate of 77.8% compared with 85.5% and 86.8% for 
patients that had complete PTV coverage or absence of fluid 
collection, respectively, without statistical significance. Post-
PORT complications developed in 5 (6.6%) patients, of which 
4 had fluid collection. Wound complication developed in 3 
(8.6%) of 35 patients with fluid collection and in 1 (2.4%) of 
41 patients without fluid collection. 
 
Conclusion: Fluid collection demonstrated lower LC rates 
after wide excision and PORT for STS, but with a reasonable 
wound complication rate of 8.6% when compared with rates 
of previous studies ranging from 5-17%. Furthermore, partial 
coverage of fluid collections in PTVs had worse LC rates, thus 
recommending complete coverage. Future evaluation wth a 
larger number of cases will be needed for statistical support 
of our findings. 
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